TAG1 and NRG Pallas have signed a letter of intent to jointly develop access to lead-212 (Pb-212) for cancer drug development across Europe.
This collaboration will combine TAG1's portable lead-212 generator with NRG Pallas' radium-224 (Ra-224) production capabilities.
The agreement builds on an existing supply arrangement under which NRG Pallas will continue to deliver high-purity Ra-224 to TAG1 through 2028. Together, the firms intend to supply preclinical and clinical quantities of lead-212 to cancer drug developers across Europe, including hospital-based adult and pediatric oncology programs.
The partnership is also exploring how its collaboration can support Lead4Life, a Dutch public–private initiative focused on developing lead-212-based radiopharmaceuticals and their supply chain.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
